|
151 |
Which GMP Requirements Apply to Stability Studies in the Pharmaceutical Industry?
|
관리자 |
2026-05-06 |
290 |
|
150 |
FDA's 483 Playbook: What It Means For Pharma Outsourcing — And What It Doesn't Address
|
관리자 |
2026-05-06 |
311 |
|
149 |
All The Ways Global Biopharma Still Grapples With Annex 1
|
관리자 |
2026-05-06 |
74 |
|
148 |
The Capacity Myth—and What Actually Matters
|
관리자 |
2026-02-27 |
758 |
|
147 |
Process Engineering's Key Role In Sterile Injectable Facility Design
|
관리자 |
2026-02-27 |
703 |
|
146 |
When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025
|
관리자 |
2026-02-27 |
435 |
|
145 |
How to Design Your Pharmaceutical Facility Disinfection Programme Cleanroom
|
관리자 |
2026-01-30 |
731 |
|
144 |
Why Use Total Organic Carbon Analysis For Cleaning Validation?
|
관리자 |
2026-01-30 |
565 |
|
143 |
Building Enterprise Resilience From QRM Signals
|
관리자 |
2026-01-30 |
602 |
|
142 |
Contamination Control Strategies In Low Bioburden Biologic Drug Substance Manufacturing
|
관리자 |
2026-01-05 |
816 |
